Increased Anxiety and Length of Treatment Associated With Depressed Patients Who are Readmitted to Collaborative Care

Journal of Primary Care & Community Health

Volumn 2, Issue 2, 2011, Pages 82-86

  Angstman, Kurt B ^a   Maclaughlin, Kathy L ^a   Williams, Mark D ^a   Rasmussen, Norman H ^a   Dejesus, Ramona S ^a  

^a MAYO CLINIC   (United States)

Author keywords

depression; disease management; health outcomes; managed care; primary care

Indexed keywords

EID: 84990350787     PISSN: 21501319     EISSN: 21501327     Source Type: Journal    
DOI: 10.1177/2150131910387932     Document Type: Article

References (18)

1. Gelenberg AJ. The prevalence and impact of depression. J Clin Psychiatry. 2010;71:e06.
2. Unutzer J Katon W Callahan CM. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288:2836-2845.
3. Katon WJ Schoenbaum M Fan MY. Cost-effectiveness of improving primary care treatment of late-life depression. Arch Gen Psychiatry. 2005;62:1313-1320.
4. Gilbody S Bower P Fletcher J Richards D Sutton AJ. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006;166:2314-2321.
5. Katon W Unutzer J Fan MY. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care. 2006;29:265-270.
6. Angstman K Williams M. Patients in a depression collaborative care model of care: comparison of six month cost utilization data with usual care. J Prim Care Community Health. 2010;1:12-16.
7. Angstman K DeJesus R Williams M. Collaborative care management for depression: cost metrics compared to usual care and with clinical response. J Prim Care Community Health. 2010;1:73-77.
8. Papakostas GI McGrath P Stewart J. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res. 2008;161:116-120.
9. Katon W Unutzer J Russo J. Major depression: the importance of clinical characteristics and treatment response to prognosis. Depress Anxiety. 2010;27:19-26.
10. McGrath PJ Stewart JW Quitkin FM. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163:1542-1548.
11. Nierenberg AA Husain MM Trivedi MH. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 40:41-50.
12. Andreescu C Lenze EJ Dew MA. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry. 2007;190:344-349.
13. Hannan C Lambert MJ Harmon C. A lab test and algorithms for identifying clients at risk for treatment failure. J Clin Psychol. 2005;61:155-163.
14. Lin EH Katon WJ VonKorff M. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med. 1998;7:443-449.
15. Spitzer RL Kroenke K Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282:1737-1744.
16. Reinert DF Allen JP. The alcohol use disorders identification test: an update of research findings. Alcohol Clin Exp Res. 2007;31:185-199.
17. Spitzer RL Kroenke K Williams JB Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092-1097.
18. Hirschfeld RM Calabrese JR Weissman MM. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003;64:53-59.